UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
RxSight, Inc.
RxSight, Inc. RXST | 0.00 |
UBS analyst Patrick Wood maintains RxSight (NASDAQ:
RXST) with a Neutral and raises the price target from $5.5 to $6.3.
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
RxSight, Inc. RXST | 0.00 |